Company news
Neurocrine Biosciences, Inc. news in 2021
Neurocrine Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.
Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease
December 6, 2021
Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer
November 29, 2021
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
November 21, 2021
Neurocrine Biosciences Reports Third Quarter 2021 Financial Results
October 31, 2021
Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021
October 31, 2021
Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting
October 15, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
October 10, 2021
Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic
October 7, 2021
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
August 4, 2021
Neurocrine Biosciences Reports Second Quarter 2021 Financial Results
August 2, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
July 18, 2021
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
May 4, 2021
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
April 15, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
April 13, 2021
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
March 1, 2021
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
February 3, 2021
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
January 19, 2021
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
January 7, 2021
Calls in 2021
Decks in 2021
- Q2 2021 Earnings Presentation
Earnings · 36 slides · Aug 3, 2021